Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-440-4 | CAS number: 27394-99-6
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 980
- Report date:
- 1980
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Principles of method if other than guideline:
- BASF-Test
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- N-(1-cyanoethyl)formamide
- EC Number:
- 248-440-4
- EC Name:
- N-(1-cyanoethyl)formamide
- Cas Number:
- 27394-99-6
- Molecular formula:
- C4H6N2O
- IUPAC Name:
- N-(1-cyanoethyl)formamide
- Details on test material:
- N-Formylalaninnitril (purity 98%)
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- no data
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- no data
- Doses:
- 100, 464, 681, 1000, 1470, 2150 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Other examinations performed: clinical signs, body weight - Statistics:
- no data
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 870 mg/kg bw
- Mortality:
- Dose 2150mg/kg: 4 male animals died after 1 day; 1 female animal died after 1 day,2 female animal died after 2 days,1 female animal died after 7 days
Dose 1470 mg/kg: 5 male animals died afer 1 day; 4 female animals died after 1 day
Dose 1000 mg/kg: 5 male animals died afer 1 day; 4 female animals died after 1 day
Dose 681 mg/kg: 2 male animals died after 1 day, 1 male animal died after 2 days - Clinical signs:
- other: Dyspnoea, apathy, abnormal position, staggering, tremor, spastic gait, piloerection, erythema, exsiccosis, poor general state
- Gross pathology:
- Dead animals:
Heart: acute atrial dilatation; acute congestive hyperemia; liver: broadened periphery of the hepatic lobules; kidney: slightly brightened;
stomach: sporadic bloody ulcerations.
Sacrificed animals: NAD
Any other information on results incl. tables
The LD50 was determined to be 870 mg/kg bw.
SYMPTOMS:
The following symptoms were observed in the different dose groups:
Symptom (2150 / 1470 / 1000 / 681 / 464 / 100 mg/kg bw):
dyspnoea (+/+/+/+/+/-)
apathy (+/+/+/+/+/+)
abnormal position (-/+/+/+/-/-)
staggering (+/+/+/+/-/-)
dyspnoea (+/+/+/+/+/-)
tremor (-/+/+/+/-/-)
spastic gait (+/-/-/-/+/-)
(tonic-clonic) convulsions (-/+/+/-/-/-)
piloerection (+/+/+/+/+/+)
erythema (+/+/+/+/+/+)
exsiccosis (+/+/-/+/-/-)
salivation (-/+/-/-/-/-)
poor general state (+/+/+/+/+/-)
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
